Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

China Passes Comprehensive New Drug Administrative Law

publication date: Aug 29, 2019

China has passed a broad Amendment to its Drug Administrative Law, codifying the far-reaching changes to the country's drug approval/administration rules made over the last four years while also significantly increasing punishments for infractions. The new regulations affect almost every part of the biopharma industry. For example, the very successful Marketing Administration Holder rules, which allow a company to outsource manufacturing of its products, will be expanded to all of China from the test provinces. In addition, new regulations to protect China's population from counterfeit or substandard vaccines will carry financial punishments of 10 to 50 times their value, much higher than previous punitive fines. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China